Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly
From Pharmaceutical Executive · · 3 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.